Last reviewed · How we verify
Oral Sulfate Tablet 2-Day
Oral Sulfate Tablet 2-Day is a Osmotic laxative Small molecule drug developed by Pharmbio Korea Co., Ltd.. It is currently in Phase 3 development for Constipation, Bowel preparation.
Oral sulfate acts as an osmotic laxative that draws water into the intestinal lumen to promote bowel evacuation.
Oral sulfate acts as an osmotic laxative that draws water into the intestinal lumen to promote bowel evacuation. Used for Constipation, Bowel preparation.
At a glance
| Generic name | Oral Sulfate Tablet 2-Day |
|---|---|
| Sponsor | Pharmbio Korea Co., Ltd. |
| Drug class | Osmotic laxative |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Sulfate salts are poorly absorbed in the gastrointestinal tract and create an osmotic gradient that increases intraluminal fluid volume, stimulating peristalsis and facilitating stool passage. The 2-day formulation likely refers to a dosing regimen or extended-release delivery designed to provide sustained laxative effect over a 48-hour period.
Approved indications
- Constipation
- Bowel preparation
Common side effects
- Abdominal cramping
- Diarrhea
- Nausea
- Bloating
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Efavirenz for the Treatment of Creutzfeldt-Jakob Disease (PHASE3)
- Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder (PHASE2)
- "Intra-articular Hyaluronic Acid Injection for Accelerating Functional Recovery After Knee Arthroscopy" (NA)
- Venetoclax Basket Trial for High Risk Hematologic Malignancies (PHASE1)
- A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Sulfate Tablet 2-Day CI brief — competitive landscape report
- Oral Sulfate Tablet 2-Day updates RSS · CI watch RSS
- Pharmbio Korea Co., Ltd. portfolio CI
Frequently asked questions about Oral Sulfate Tablet 2-Day
What is Oral Sulfate Tablet 2-Day?
How does Oral Sulfate Tablet 2-Day work?
What is Oral Sulfate Tablet 2-Day used for?
Who makes Oral Sulfate Tablet 2-Day?
What drug class is Oral Sulfate Tablet 2-Day in?
What development phase is Oral Sulfate Tablet 2-Day in?
What are the side effects of Oral Sulfate Tablet 2-Day?
Related
- Drug class: All Osmotic laxative drugs
- Manufacturer: Pharmbio Korea Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Constipation
- Indication: Drugs for Bowel preparation
- Compare: Oral Sulfate Tablet 2-Day vs similar drugs
- Pricing: Oral Sulfate Tablet 2-Day cost, discount & access